Tag:

Pfizer

Latest Headlines

Latest Headlines

Pfizer continues spending spree with $295M upfront for PhIII growth hormone

Pfizer's business development team is on a spending spree. Today the pharma giant said it is partnering with Miami-based Opko Health on a Phase III long acting growth hormone, paying $295 million upfront and promising up to $275 million more on regulatory milestones.

Pfizer turns to app to overcome rare disease enrollment bottleneck

Pfizer is experimenting with a mobile app to enroll rare disease patients in a study. The trial is comparing the DNA of people with congenital analgesia to unaffected family members.

Pfizer tosses out HR rules with 'American Idol' recruiting in Sweden

Everyone who's ever applied for a job fears that recruiters will glance at their resumes and toss them out. Apparently, Pfizer's Swedish operation feared the same thing--and it tossed out the whole process.

Indonesia's Indofarma combines its manufacturing expertise with Kimia's supply chain strength

Indonesia is one of those emerging markets that has pressured outside companies to produce locally and companies like Pfizer, Merck and Fresenius Kabi have all built or expanded plants there in recent years. But the government, which controls some of the players, is taking steps to improve efficiency in the domestic market, pushing for a merger that ties the manufacturing expertise of one company to the supply chain strength of another.

Another Pfizer blockbuster bites the dust as Celebrex generics roll

Look out, Pfizer--the generics are here. On Wednesday, Teva and Mylan both launched versions of the company's arthritis med Celebrex, meaning Pfizer is about to watch the sales decline of yet another blockbuster.

Pfizer strikes another immunotherapy deal to widen its oncology pipeline

With its designs on AstraZeneca at least temporarily abandoned, Pfizer has set out to create an immuno-oncology portfolio of its own, signing a deal with a Belgian biotech to get its hands on treatments that promise to sharpen the body's anticancer weaponry.

Pfizer buys into gene therapy's renaissance and bets on Spark Therapeutics

Pfizer is the latest pharma heavyweight to get behind the promise of gene therapy, as the New York drugmaker has laid out plans to set up a dedicated R&D operation and signed a deal with startup Spark Therapeutics to kick-start the effort.

Rare disease could be the gateway to billions for PCSK9 drugs

About 1.5 million Americans suffer from familial hypercholesterolemia, an inherited disease that leads to dangerously high cholesterol, and they're likely to be the first targets for a new class of drugs that promise to bring in blockbuster sales.

With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet

With a months-long hostile pursuit from Valeant and failed talks to buy North Carolina's Salix, Allergan had already been on an M&A roller coaster this year before finally agreeing to sell itself to Actavis last month. And options traders, for one, are afraid the ride's not over yet.

Pfizer believes a dose of confidence will help it sell biosimilars

As drug prices climb and expensive newcomers inspire payers to get creative to contain costs, a window is widening for meds that can drive efficiency for healthcare systems and address consumers' needs. That's where biosimilars come in--or so Pfizer figures.